Alcyone Therapeutics Inc.

Alcyone's CSO, Dr. Kathrin Meyer will be presenting poster #po979 on Thursday October 24th at 2pm CET. Please come by. #ESGCT #rome #thecaflexdrx

The groundbreaking discovery of microRNAs has been recognized with the Nobel Prize in Physiology or Medicine, paving the way for revolutionary therapies at Alcyone Therapeutics, we're thrilled to be at the forefront of translating this fundamental research into potentially life-changing treatments for patients with CNS disorders. ? Our innovative miREX? platform harnesses the power of microRNA regulation to develop precision therapies for neurological conditions. Our lead candidate, XGR-101, is the first miRNA sponge gene therapy designed to reactivate the silenced X-chromosome, offering hope for patients with Rett Syndrome and other X-linked disorders. ? We extend our heartfelt congratulations and gratitude to the Nobel laureates whose pioneering work laid the foundation for this exciting field. Their discoveries have opened new possibilities in medicine, and we're honored to build upon their legacy as we work to bring transformative therapies to patients in need. ? At Alcyone, we're committed to pushing the boundaries of science and medicine. Stay tuned as we continue to advance our pipeline of miRNA-targeted therapies for CNS disorders, including Rett Syndrome, Fragile X, X-ALD, and CMTX. ? The future of precision medicine for neurological conditions is here, and we're proud to be leading the charge. #NobelPrize #microRNA #GeneTherapy #RareDisease #CNSdisorders #Biotech #Innovation PJ Anand Deep Singh Kathrin Meyer Sanchita Bhatnagar, Ph.D Ajay Verma

Dr. Kathrin Meyer, CSO will be presenting poster #po307 on Tuesday October 22nd at 7:30 pm CET. Join her #ESGCT #Rome #RettSyndrome #generegulation #csf

Our CSO, Dr. Kathrin Meyer?is attending the 2024 ESGCT conference in Rome next week. If you’re attending, let us know and we will arrange a meetup! #ESGCT #GeneTherapy #CellTherapy #Networking

At Alcyone, it is our mission to deliver impactful change to people living with SMA and other neurological conditions.

Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx? System for Administration of nusinersen >> https://rb.gy/9jimpl

Come visit us at booth T5 2024 Annual SMA Conference held at JW Marriott Austin in Austin, Texas. hashtag #curesma

We’re proud to join forces with other biopharma companies and participate in BioBall 2024, an incredible fundraising event supporting Special Olympics Massachusetts. This event is a unique opportunity to unite our industry in championing these inspiring athletes. Inclusion, teamwork, and the power of community - excited to make a difference together!? #BioBall #SpecialOlympics #BiotechCommunity #Fundraising #Teamwork #Support?

Our very own Cassandra Dennys, Ph.D and Chris Fleege will be presenting a patient poster tonight at the 2024 Annual SMA Conference titled, ThecaFlex DRx System: Implantable intrathecal catheter and subcutaneous port platform under investigation for repeat intrathecal delivery of therapeutics to the central nervous system

This week we are at the 2024 Annual SMA Conference held at JW Marriott Austin in Austin, Texas. #curesma